145 related articles for article (PubMed ID: 16019528)
1. Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patients.
Cornillon J; Fawaz A; Depil S; Dufosse F; Duhamel A; Bauters F; Fenaux P; Jouet JP; Yakoub-Agha I
Leuk Lymphoma; 2005 Jun; 46(6):841-9. PubMed ID: 16019528
[TBL] [Abstract][Full Text] [Related]
2. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
[TBL] [Abstract][Full Text] [Related]
3. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine.
Visani G; Olivieri A; Malagola M; Brunori M; Piccaluga PP; Capelli D; Pomponio G; Martinelli G; Isidori A; Sparaventi G; Leoni P
Leuk Lymphoma; 2006 Jun; 47(6):1091-102. PubMed ID: 16840201
[TBL] [Abstract][Full Text] [Related]
4. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
5. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
Suciu S; Mandelli F; de Witte T; Zittoun R; Gallo E; Labar B; De Rosa G; Belhabri A; Giustolisi R; Delarue R; Liso V; Mirto S; Leone G; Bourhis JH; Fioritoni G; Jehn U; Amadori S; Fazi P; Hagemeijer A; Willemze R;
Blood; 2003 Aug; 102(4):1232-40. PubMed ID: 12714526
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
8. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.
Yu S; Fan Z; Ma L; Wang Y; Huang F; Zhang Q; Huang J; Wang S; Xu N; Xuan L; Xiong M; Han L; Sun Z; Zhang H; Liu H; Yu G; Shi P; Xu J; Wu M; Guo Z; Xiong Y; Duan C; Sun J; Liu Q; Zhang Y
JAMA Netw Open; 2021 Jul; 4(7):e2115991. PubMed ID: 34232303
[TBL] [Abstract][Full Text] [Related]
9. Comparison of allo-SCT, auto-SCT and chemotherapy for the treatment of patients with low- or intermediate-risk acute myeloid leukemia: a network meta-analysis.
Ye W; Wu X; Zhao R; Jin X; Li H; Qu Y; Ji J; Liu Z
Stem Cell Res Ther; 2024 May; 15(1):153. PubMed ID: 38816870
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia.
Zheng C; Zhu X; Tang B; Yao W; Song K; Tong J; Geng L; Liu H; Sun Z
Ann Hematol; 2015 Mar; 94(3):473-80. PubMed ID: 25217231
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
12. Dose-intensive therapy for adult acute lymphoblastic leukemia.
Finiewicz KJ; Larson RA
Semin Oncol; 1999 Feb; 26(1):6-20. PubMed ID: 10073558
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.
Nishiwaki S; Inamoto Y; Sakamaki H; Kurokawa M; Iida H; Ogawa H; Fukuda T; Ozawa Y; Kobayashi N; Kasai M; Mori T; Iwato K; Yoshida T; Onizuka M; Kawa K; Morishima Y; Suzuki R; Atsuta Y; Miyamura K
Blood; 2010 Nov; 116(20):4368-75. PubMed ID: 20664060
[TBL] [Abstract][Full Text] [Related]
15. Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia.
Crotta A; Zhang J; Keir C
Curr Med Res Opin; 2018 Mar; 34(3):435-440. PubMed ID: 28945102
[TBL] [Abstract][Full Text] [Related]
16. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial.
Ribera JM; Ortega JJ; Oriol A; Bastida P; Calvo C; Pérez-Hurtado JM; González-Valentín ME; Martín-Reina V; Molinés A; Ortega-Rivas F; Moreno MJ; Rivas C; Egurbide I; Heras I; Poderós C; Martínez-Revuelta E; Guinea JM; del Potro E; Deben G
J Clin Oncol; 2007 Jan; 25(1):16-24. PubMed ID: 17194902
[TBL] [Abstract][Full Text] [Related]
18. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
19. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
Kuhlen M; Willasch AM; Dalle JH; Wachowiak J; Yaniv I; Ifversen M; Sedlacek P; Guengoer T; Lang P; Bader P; Sufliarska S; Balduzzi A; Strahm B; von Luettichau I; Hoell JI; Borkhardt A; Klingebiel T; Schrappe M; von Stackelberg A; Glogova E; Poetschger U; Meisel R; Peters C
Br J Haematol; 2018 Jan; 180(1):82-89. PubMed ID: 29193007
[TBL] [Abstract][Full Text] [Related]
20. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.
Piemontese S; Ciceri F; Labopin M; Arcese W; Kyrcz-Krzemien S; Santarone S; Huang H; Beelen D; Gorin NC; Craddock C; Gulbas Z; Bacigalupo A; Mohty M; Nagler A;
J Hematol Oncol; 2017 Jan; 10(1):24. PubMed ID: 28103944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
